Trustee of Dartmouth Medical School and a clinical professor of ophthalmology at New York University. He is past president of American Society of Cataract and Refractive Surgery, president-elect of the International Intraocular Implant Society and is the editor-in-chief of EyeWorld. He has written over 200 peer review papers and 60 book chapters and books. He is a Fellow of the American Academy of Ophthalmology and has received its Lifetime Achievement Award.
Professor of Ophthalmology at University of Paris and Head of the department of Ophthalmology at Lariboisière University Hospital (Paris, France). He has authored more than 140 medical and scientific articles and has made numerous contributions to ophthalmology textbooks. Dr. Tadayoni completed undergraduate training in medicine at the University of Marseille, and his M.D. and internship at Paris V University. He completed his studies with a retina fellowship at Lariboisière University Hospital. Simultaneously, he pursued his Ph.D. in Science at Paris VII University and the Paris Vision Institute.
Christophe Baudouin, M.D. Ph.D., is professor of Ophthalmology since 1995 and the Chairman of the Department of Ophthalmology in Quinze-Vingts National Ophthalmology Hospital, Paris, as well as the President of the Medical Council since 2016. Pr. Baudouin is also the Director of an INSERM-labelled research group, and a member of the International Council of Ophthalmology (ICO)’s board. He is currently the President of the European Dry Eye Society, Editor-in-Chief of the French Journal of Ophthalmology, Vice-President of the French Glaucoma Society, and an active member of several international societies, including the prestigious American Ophthalmological Society and Academia Ophthalmologica Internationalis. With a Gold Medal Thesis Prize, Pr. Baudouin achieved his M.D. in Nice in 1989 and obtained his Ph.D. in Paris in 1992.
Managing Partner of Retinal Consultants of Arizona, Founding Member of the Spectra Eye Institute and Clinical Professor at the Department of Ophthalmology at the Keck School of Medicine, University of Southern California. Globally recognized as a clinical researcher, having served as Principal Investigator for over 100 multicenter clinical trials for emerging and FDA-approved therapies for wet age-related macular degeneration including Beovu®, Lucentis® and Eylea®. Dr. Dugel has authored more than 200 papers and 35 book chapters. He is on the Editorial Board of several major medical journals.
Peter K. Kaiser, M.D., is Chaney Family Endowed Chair in Ophthalmology Research and a Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine. Pr. Kaiser is actively involved in clinical research and has been principal investigator in over 60 trials evaluating new treatments for AMD, DR, and other retinal disorders. He is Editor-in-Chief of Retinal Physician, Associate Editor of International Ophthalmology Clinics, and serves on the editorial boards of American Journal of Ophthalmology, Retina, Retina Today, and Ocular Surgery News. Pr. Kaiser has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with Achievement and Senior Achievement Awards and has been listed as one of the top 100 most influential people in the world of ophthalmology. Pr. Kaiser graduated magna cum laude with Highest Honors from Harvard College and magna cum laude from Harvard Medical School.
Arshad M. Khanani, M.D., M.A., FASRS founded the clinical research section at Sierra Eye Associates, and currently serves as its Managing Partner, Director of Clinical Research, and Director of Fellowship. He has been a principal investigator for more than 100 clinical trials and a top enroller in the United States for multiple Phase 1-3 trials. He is also a Clinical Associate Professor at the University of Nevada, Reno School of Medicine. Dr. Khanani is an elected member of the Retina Society, Macula Society and has received numerous awards of distinction. He has received the Senior Honor Award from the American Society of Retina Specialists (ASRS) and was also awarded the prestigious ASRS Presidents’ Young Investigator Award in 2021.
Anat Loewenstein, M.D., MHA, is Professor of Ophthalmology, Chairman of the Division of Ophthalmology at the Tel Aviv Medical Center, Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at Tel Aviv University, President of the Israeli Ophthalmological Society, and the General Secretary of the EURETINA board. She is a renowned retina specialist, expert in retinal toxicity, and has a strong research interest in the early detection of macular degeneration, among others. She currently serves as the Editor in Chief of the Journal Case Reports in Ophthalmology, is an associate editor of Investigative Ophthalmology & Visual Science Journal, European Journal of Ophthalmology and of Ophthalmologica. Pr. Loewenstein published more than 450 papers in peer reviewed journals and contributed multiple chapters to ophthalmology textbooks. She is also actively involved as a leader in mentorship of young retina specialists including the mentorship educational programs of ARVO and EURETINA.
Dr. Sabri Markabi is the former global Head of R&D and CMO of Alcon, and has worked in the pharmaceutical industry for more than 20 years in global drug development leadership positions. In particular, he headed the clinical Neuroscience department then the Global Ophthalmics Development group at Novartis Pharma before joining Alcon, the pharmaceutical and medical device ophthalmology leader, where he worked between 2008 and 2015. Since 2016, he has advised health care organizations on topics including investment and R&D strategy and is a member of the Board of Director of MedinCell, Inc.
Quan Dong Nguyen, M.D., MSc, FAAO, FARVO, FASRS is Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. Pr. Nguyen is known for his innovative work in early proof-of-concept, first-in-human clinical studies, and as principal investigator on multiple trials to evaluate potential pharmacotherapeutic agents for ocular inflammation, as well as for retinal vascular and uveitis. He is on the Editorial Board of key journals, including the Journal of Ophthalmic Infection and Inflammation and Ophthalmic Surgery, Lasers and Imaging Retina. He has been elected to many prestigious national and international professional organizations, including the American Academy of Ophthalmology, the Macula Society, the Retina Society, the American Society of Retina Specialists, the Club Jules Gonin, the American Ophthalmological Society, the International Uveitis Study Group, the American Uveitis Society, and the International Ocular Inflammation Society. He completed fellowships in Immunology and Uveitis at the Massachusetts Eye and Ear Infirmary, in Ocular Immunology at the Wilmer Eye Institute of the Johns Hopkins Medical Institutions, and in Medical and Surgical Retina at the Schepens Eye Research Institute and the Massachusetts Eye and Ear Infirmary.
Dr. Stefánsson is a leading physician in the field of diabetic eye disease and diabetic eye screening. Dr. Stefánsson has co-founded four biotechnology firms in addition to Oculis, including Cyclops ehf. which was acquired by DeCode Genetics in 2000. He contributes to a number of ophthalmological publications either as chief editor or on the editorial board. Dr. Stefánsson was knighted by the President of Iceland in 2007 and received a number of awards in science and ophthalmology, such as Iceland’s highest award in science in 2008 and the gold medal of the European Academy of Ophthalmology in 2014 among many other honours. Dr. Stefánsson has published more than 300 peer-reviewed international publications, more than 400 abstracts, numerous book chapters and patents. Dr. Stefánsson received a degree in medicine from the University of Iceland Medical School and a Ph.D. in physiology from Duke University followed by a residency and faculty position at Duke. He has served as Vice Dean and Dean of the Faculty of Medicine at the University of Iceland and served as Professor and Chair of the Department of Ophthalmology at the National University Hospital in Iceland since 1993.
Pablo Villoslada, M.D., is an Adjunct Professor at Stanford University. He has been active in neuroscience and brain disease research for more than 20 years, contributing to the application of systems biology to neurological diseases, development of new therapies or biomarkers for multiple sclerosis and neuro-ophthalmologic diseases, and developing new neuroimaging technologies for monitoring brain diseases. Prior to taking up his position at Stanford, he was Medical Director of Neuroinflammation at Genentech. His experience also includes roles as Professor at the Department of Neurology, University of California, San Francisco, and Group Leader of the Neuroimmunology group of the Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona. He received his M.D. at the University of Santiago de Compostela, Spain in 1990, his speciality in neurology in 1995 at the Hospital Vall d’Hebron, Spain and his Ph.D. in neuroimmunology in 1996 at the Autonomous University of Barcelona.